Investors

Copyright West LLC. Minimum 15 minutes delayed.

News Release

<< Back
Mar 17, 2015

AUGMENT Fertility Treatment to be Highlighted at Society for Reproductive Investigation (SRI) Annual Meeting

First Clinical Experience Presentations to Include Initial Pregnancy Data

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 17, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that in vitro fertilization (IVF) specialists from select international clinics will present initial clinical experience with OvaScience’s AUGMENTSM fertility treatment during the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting March 25-28, 2015 in San Francisco, CA.

These presentations will be the first time detailed clinical reports of the AUGMENT treatment will be made available. The AUGMENT treatment is a fertility treatment specifically designed to use the mitochondria, or energy, from a woman’s own egg precursor cells – immature egg cells found inside the protective ovarian lining – to improve egg health. Improved egg health is important for fertilization and embryo development during in vitro fertilization (IVF). The treatment is available to patients in select international IVF clinics. The AUGMENT treatment is not available in the United States.

Presentations summarizing preliminary patient outcomes with the AUGMENT treatment, including early pregnancy information from patients who previously failed one or more IVF cycles, will include:

  • Preliminary Results with Autologous Egg Precursor Cell Mitochondrial Injection During Intracytoplasmic Sperm Injection (ICSI) in Women with Previous Poor Embryo Development
    • Presenter: Robert F. Casper, M.D., F.R.C.S.(C), TCART Fertility Partners, Toronto, Ontario
    • Abstract LB – 002, Poster Presentation, Thursday, March 26 at 10:00 am PST, Grand Ballroom A&B
  • Oogonial Precursor Cell Derived Autologous Mitochondria Injection Improves Outcomes in Women with Multiple IVF Failures Due to Low Oocyte Quality
    • Presenter: Kutluk Oktay, M.D., F.A.C.O.G, Gen-art IVF, Ankara, Turkey
    • Abstract LB – 044, Poster Presentation, Saturday, March 28 at 7:45 am PST, Grand Ballroom A&B

More information about the SRI Annual Meeting and abstracts is available at www.sri-online.org.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s business and development plans for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

###

Source: OvaScience

OvaScience
Investors
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
tmcneely@ovascience.com
or
Media
Cara Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com